Risks of Bacterial and Fungal Superinfection in Patients With COVID-19

Risks of Bacterial and Fungal Superinfection in Patients With COVID-19 Stratified by New and Pre-existing Immunosuppression: a Retrospective, Observational, Multisite, Multinational Cohort Study

Infection with bacteria or fungi can be deadly. Often, these types of infections can lead to an increase in the severity of illness requiring intensive care unit (ICU) admission, prolonged duration of treatment and further risks associated with additional infections and superinfections. These are also called hospital acquired secondary infections. Patients who contract COVID-19 and require an ICU admission are at increased risk of contracting these secondary infections, and receive certain medications that can lower your body's immune response. In COVID-19 patients who require these treatments, it is unclear what affect these medications can have on developing an additional infection as well as the rate of recovery/survival. This study is evaluating the effect these medications have on the development of secondary infections and rate of survival of COVID-19 patients that have been admitted to ICUs.

Inclusion Criteria:

• Hospital admission date from 1 July 2020 to 30 June 2021
• Positive test for COVID-19 collected within 1 week of admission date
• ICU admission within 60 days after hospital admission date

Exclusion Criteria:

• Hospital admission shorter than 5 days
• Persons younger than 18 years of age